Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Neuroendocrine Tumors: Treatment and Management Volume II
share announcement

Neuroendocrine Tumors: Treatment and Management Volume II

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".

Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 6534

Special Issue Editor

Prof. Dr. Alessio Imperiale

E-Mail Website
Guest Editor
Department of Nuclear Medicine, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France
Interests: nuclear medicine; PET imaging; neuroendocrine tumors; PRRT; paraganglioma; pheochromocytoma; thyroid medullary carcinoma; infection
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This collection is the second edition of the previous one “Neuroendocrine Tumors: Treatment and Management”

Neuroendocrine tumors (NET) are rare and heterogeneous epithelial neoplasms with neuroendocrine differentiation, commonly originating from the gastrointestinal tract, pancreas, and lung. Patients with suspected or known NET are usually referred to a multidisciplinary skilled team for diagnostic evaluation, treatment, and follow-up. Whenever feasible, surgery is proposed for low-grade tumors. Multiple therapeutic options are available for unresectable advanced disease or metastatic disease, including medical treatment with cold somatostatin analogs, peptide receptor radionuclide therapy (PRRT), chemotherapy, and molecule-targeted therapies such as mammalian target of rapamycin (mTOR) inhibitors and antiangiogenic agents. Moreover, recent advances in understanding the genetic and epigenetic alterations in NET as well as the knowledge of proteomics and metabolomics tumoral features could make novel targets available for future therapeutic options and for the assessment of patient prognosis. In this Special Issue, a panel of internationally recognized experts in this field will focus on the current diagnostic approach, the several available therapeutic approaches, and the future directions for the management of patients with lung and gastroenteropancreatic NET.

Prof. Dr. Alessio Imperiale
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1063 KiB  
Article
Hepatic Hilar Block as an Adjunct to Transarterial Embolization of Neuroendocrine Tumors: A Retrospective Review of Safety and Efficacy
by Samagra Jain, Harrison Blume, Lee Rodriguez, Elena Petre, Amgad Moussa, Ken Zhao, Vlasios Sotirchos, Nitya Raj, Diane Reidy, Etay Ziv and Erica Alexander
Cancers 2023, 15(21), 5202; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15215202 - 29 Oct 2023
Viewed by 723
Abstract
Purpose: This study investigates whether hepatic hilar nerve blocks (HHNB) provide safe, effective analgesia in patients with neuroendocrine tumors (NET) treated with transarterial embolization (TAE). Methods: The retrospective study included all NETs treated with TAE or TAE + HHNB from 1/2020 to 8/2022. [...] Read more.
Purpose: This study investigates whether hepatic hilar nerve blocks (HHNB) provide safe, effective analgesia in patients with neuroendocrine tumors (NET) treated with transarterial embolization (TAE). Methods: The retrospective study included all NETs treated with TAE or TAE + HHNB from 1/2020 to 8/2022. Eighty-five patients (45 men), mean age 62 years, were treated in 165 sessions (TAE, n = 153; TAE + HHNB, n = 12). For HHNBs, ≤10 mL bupivacaine HCl 0.25% ± 2 mg methylprednisolone were injected under ultrasound guidance. The aims were to assess safety of HHNB and reduction in pain. Groups were compared with Pearson’s chi-squared and Wilcoxon rank sum tests. Logistic regression assessed independent risk factors for pain. Results: No immediate complications from HHNBs were reported. No difference in incidence of major complications between TAE and TAE + HHNB one month post-embolization was observed (7.19% vs. 8.33%, p = 0.895). No differences in mean length of hospital stay after treatment were observed (TAE 2.2 days [95%CI: 1.74–2.56] vs. TAE + HHNB 2.8 days [95%CI: 1.43–4.26]; p = 0.174). Post-procedure pain was reported in 88.2% of TAE and 75.0% of TAE + HHNB patients (p = 0.185). HHNB recipients were more likely to use analgesic patches (25.0% vs. 5.88%; p = 0.014). No other differences in analgesic use were observed. Conclusions: HHNBs can safely be performed in patients with NETs. No difference in hospital stays or analgesic drug use was observed. Managing pain after TAE is an important goal; further study is warranted. Full article
(This article belongs to the Special Issue Neuroendocrine Tumors: Treatment and Management Volume II)
►▼ Show Figures

Figure 1

10 pages, 1595 KiB  
Article
Defining MRI Superiority over CT for Colorectal and Neuroendocrine Liver Metastases
by Marc A. Attiyeh, Gautam K. Malhotra, Daneng Li, Saro B. Manoukian, Pejman M. Motarjem and Gagandeep Singh
Cancers 2023, 15(20), 5109; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15205109 - 23 Oct 2023
Viewed by 1103
Abstract
Background: We compared CT and MRI for staging metastatic colorectal or neuroendocrine liver metastases (CRLMs and NELMs, respectively) to assess their impact on tumor burden. Methods: A prospectively maintained database was queried for patients who underwent both imaging modalities within 3 months, with [...] Read more.
Background: We compared CT and MRI for staging metastatic colorectal or neuroendocrine liver metastases (CRLMs and NELMs, respectively) to assess their impact on tumor burden. Methods: A prospectively maintained database was queried for patients who underwent both imaging modalities within 3 months, with two blinded radiologists (R1 and R2) independently assessing the images for liver lesions. To minimize recall bias, studies were grouped by modality, and were randomized and evaluated separately. Results: Our query yielded 76 patients (42 CRLMs; 34 NELMs) with low interrater variability (intraclass correlation coefficients: CT = 0.941, MRI = 0.975). For CRLMs, there were no significant differences in lesion number or size between CT and MRI. However, in NELMs, Eovist®-enhanced MRI detected more lesions (R1: 14.3 vs. 12.1, p = 0.02; R2: 14.4 vs. 12.4, p = 0.01) and smaller lesions (R1: 5.7 vs. 4.4, p = 0.03; R2: 4.8 vs. 2.9, p = 0.02) than CT. Conclusions: CT and MRI are equivalent for CRLMs, but for NELMs, MRI outperforms CT in detecting more and smaller lesions, potentially influencing treatment planning and surgery. Full article
(This article belongs to the Special Issue Neuroendocrine Tumors: Treatment and Management Volume II)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 854 KiB  
Review
A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients
by Morticia N. Becx, Noémie S. Minczeles, Tessa Brabander, Wouter W. de Herder, Julie Nonnekens and Johannes Hofland
Cancers 2022, 14(23), 5792; https://doi.org/10.3390/cancers14235792 - 24 Nov 2022
Cited by 11 | Viewed by 4174
Abstract
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]-octreotate (177Lu-DOTATATE) has become an established second- or third-line treatment option for patients with somatostatin receptor (SSTR)-positive advanced well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Clinical evidence of the efficacy [...] Read more.
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]-octreotate (177Lu-DOTATATE) has become an established second- or third-line treatment option for patients with somatostatin receptor (SSTR)-positive advanced well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). Clinical evidence of the efficacy of PRRT in tumor control has been proven and lower risks of disease progression or death are seen combined with an improved quality of life. When appropriate patient selection is performed, PRRT is accompanied by limited risks for renal and hematological toxicities. Treatment of NET patients with PRRT requires dedicated clinical expertise due to the biological characteristics of PRRT and specific characteristics of NET patients. This review provides an overview for clinicians dealing with NET on the history, molecular characteristics, efficacy, toxicity and relevant clinical specifics of PRRT. Full article
(This article belongs to the Special Issue Neuroendocrine Tumors: Treatment and Management Volume II)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop